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LEPTIN/ADIPONECTIN RATIO IS AN INDEPENDENT PREDICTOR OF MORTALITY IN 
NONDIABETIC PERITONEAL DIALYSIS PATIENTS
Jung Tak Park, Tae-Hyun Yoo, Jwa-Kyung Kim, Hyung Jung Oh, Seung Jun Kim, Dong Eun Yoo, Mi Jung Lee, 
Dong Ho Shin, Seung Hyeok Han, Dae-Suk Han, and Shin-Wook Kang
Department of Internal Medicine, College of Medicine, Brain Korea 21 for Medical Science,  
Severance Biomedical Science Institute, Yonsei University, Seoul, Korea
♦ Background: The leptin/adiponectin (L/A) ratio has 
been suggested to be an atherosclerotic index for diabetic 
patients and a useful marker of insulin resistance in pa-
tients with and without diabetes. Even though end-stage 
renal disease (ESRD) patients on peritoneal dialysis (PD) 
are well characterized by abnormal adipocytokine metabo-
lism, the significance of alterations in the L/A ratio is largely 
unexplored in these patients. In this prospective study, 
we investigated the associations of leptin, adiponectin, 
and the L/A ratio with clinical outcomes in nondiabetic 
PD patients.
♦ Methods: The study included 131 stable nondiabetic ESRD 
patients who had been on PD for more than 3 months. Serum 
leptin and adiponectin levels were determined at baseline. 
Mortality was evaluated over a 5-year follow-up period.
♦ Results: During the follow-up period, 22 patients died 
(16.8%), including 10 (45.5%) as a result of cardiovascular 
disease. The L/A ratio showed a significant positive cor-
relation with body mass index [BMI (r = 0.47, p < 0.001)], 
high-sensitivity C-reactive protein (r = 0.32, p < 0.001), and 
triglycerides (r = 0.43, p < 0.001). In addition, we observed 
significant inverse correlations between the L/A ratio and 
percentage lean body mass (r = –0.30, p = 0.001) and high-
density lipoprotein cholesterol (r = –0.31, p = 0.001). In 
contrast to individual leptin and adiponectin levels, the 
L/A ratio was found to be independently associated with an 
increased mortality risk (relative risk: 1.15; 95% confidence 
interval: 1.05 to 1.27; p = 0.003) even after adjustments 
for age and BMI.
♦ Conclusions: The L/A ratio might be better related to 
patient outcomes than adipocytokines are individually in 
nondiabetic patients undergoing PD.
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Patients with chronic kidney disease are characterized by metabolic disturbances. Insulin resistance is more 
prevalent as renal function deteriorates (1). In addition, 
the levels of several adipokines are increased because 
of decreased renal clearance (2). Those features are re-
inforced in end-stage renal disease (ESRD) patients on 
peritoneal dialysis (PD), partially because of continuous 
absorption of glucose from dialysate (3,4).
In the general population, leptin and adiponectin, the 
two major adipokines, play a central role in cardiovascular 
and metabolic homeostasis. Plasma leptin levels, which 
are strongly correlated with fat mass, are independently 
linked with increased risks for myocardial infarction 
and stroke (5). In addition, higher concentrations of 
plasma leptin are associated with the development and 
prognosis of malignancies (6). In contrast, lower plasma 
adiponectin levels have been found to predict the devel-
opment of type 2 diabetes, coronary artery disease, and 
various types of cancers (6–8). Those findings associate 
both hyperleptinemia and hypoadiponectinemia with a 
worse outcome. In line with that view, the ratio of leptin 
to adiponectin (L/A) has recently been proposed for the 
evaluation of patient outcomes in the general popula-
tion. That proposal has been supported by findings that 
patients with a higher plasma L/A ratio are susceptible 
to cardiovascular events and the development of type 2 
diabetes (9,10).
However, the effects of those adipokines on clinical 
outcome in patients with chronic kidney disease are 
confounding. Lower plasma leptin and higher plasma adi-
ponectin have been shown to be independent predictors 
of mortality in patients on hemodialysis (HD) compared 
with a nonuremic population (11,12). Moreover, previous 
studies failed to demonstrate relevant associations be-
tween plasma adipokines and cardiovascular diseases in 
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ESRD patients (13,14). As already mentioned, alterations 
in adipokine metabolism are known to be remarkable in 
PD patients. Compared with ESRD patients on HD and the 
general population, PD patients show higher L/A ratios 
because of extraordinarily high levels of plasma leptin 
and a moderate degree of hyperadiponectinemia. To 
date, however, investigations into the consequences for 
patients of those abnormal adipokine levels are limited. 
Therefore, in this prospective study, we investigated 
whether plasma leptin and adiponectin or the balance 
of those adipokines is associated with clinical outcomes 
in nondiabetic PD patients.
METHODS
PATIENT POPULATION
This prospective observational study included 131 
prevalent nondiabetic ESRD patients on PD who were 
 being followed at Yonsei University Health System, 
Seoul, Korea. We recruited patients who were more 
than 18 years of age, who had maintained PD for 
more than 3 months, who had experienced no overt 
infections during the 3 months before the start of 
the study, and who had no history of malignancy or 
another chronic inflammatory disease (for example, 
rheumatoid arthritis or systemic lupus erythematosus). 
To reduce the confounding effects of glucose and lipid 
metabolism, we excluded patients with diabetes. All par-
ticipants gave informed consent before participation in 
the study.
A senior nursing clinician obtained demographic data 
through an interview. Body mass index (BMI) was calcu-
lated as weight in kilograms divided by height in meters 
squared. Baseline comorbid conditions were expressed 
as a Charlson comorbidity index (CCI) score, which was 
determined according to the International Classification 
of Diseases 10 and encompassed the period starting 6 
months before study enrollment, as described by Jassal 
et al. (15). To simulate actual dialysis conditions, all pa-
tients had a full abdomen at the time of sampling. Blood 
samples for laboratory measurements were drawn from 
the antecubital vein 2 hours after the first PD exchange 
with 1.5% dextrose dialysate while the patient was in an 
overnight fasting state. The preceding overnight dwell 
was regulated to 1.5% dextrose dialysate to standardize 
the glucose load.
LABORATORY MEASUREMENTS
Plasma was separated from blood within 30 minutes 
and stored at –70°C until analysis. Fasting blood  glucose 
was determined by the glucose oxidase method. Plasma 
total cholesterol, high-density lipoprotein (HDL) cho-
lesterol, and triglycerides (TG) were measured with 
an autoanalyzer (Hitachi 7150: Hitachi, Tokyo, Japan) 
using an enzymatic colorimetric method. Low-density 
lipoprotein (LDL) cholesterol was calculated using the 
Friedewald formula, and high-sensitivity C-reactive pro-
tein (hsCRP) was determined with a BN II analyzer (Dade 
Behring, Newarkand, DE, USA) using a latex-enhanced 
immunonephelometric method. Plasma adiponectin 
(B-Bridge International, Sunnyvale, CA, USA) and leptin 
(R&D Systems, Minneapolis, MN, USA) were measured 
using enzyme-linked immunosorbent assays.
ASSESSMENT OF DIALYSIS ADEQUACY AND LEAN BODY MASS 
USING CREATININE KINETICS
Urea kinetic studies were conducted based on a 
24-hour collection of dialysate and urine at the time of 
study enrollment. Dialysis adequacy was determined by 
using standard methods (16) to measure total weekly 
urea clearance (Kt/V urea). The normalized protein cata-
bolic rate was calculated using the Randerson equation 
and normalized to actual dry weight (17). Lean body 
mass (LBM) was estimated by creatinine kinetics, and 
the percentage LBM was calculated as LBM normalized to 
dry weight (18). Residual renal function was determined 
as the average of urea and creatinine clearances from a 
24-hour urine collection (16).
FOLLOW-UP AND ENDPOINTS
Patients were prospectively followed from April 2005 
to June 2010 or until death or transfer to an alternative 
dialysis method. The dates of transfer to HD, renal trans-
plantation, and death were defined as the endpoints. 
Mortality within 3 months of dialysis modality change was 
considered PD-related. Patients who were transferred to 
HD or who received a kidney graft were censored in the 
survival analysis.
STATISTICAL ANALYSIS
Statistical analyses were performed using SPSS for 
Windows (version 13.0: SPSS, Chicago, IL, USA). All data 
are expressed as mean ± standard deviation. Because 
of log-normal distributions of hsCRP, triglycerides, and 
leptin, natural log values were used in the analysis. Geo-
metric means for all log-normally distributed continuous 
variables were calculated and are reported with 95% 
confidence intervals (CIs). The duration of PD and the 
CCI score are reported as median values and ranges. The 
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L/A ratios are expressed as the absolute value of plasma 
leptin (nanograms per milliliter) divided by the absolute 
value of plasma adiponectin (micrograms per milliliter). 
The statistical differences between the survivor and 
non-survivor groups were determined using the Student 
t-test or the Mann–Whitney U-test for continuous vari-
ables and the chi-square test for categorical variables. 
To assess cross-sectional interrelationships between 
variables and adipokines, Spearman partial correlation 
coefficients were used after adjustment for age and 
sex. Multivariate Cox proportional hazards regression 
analyses using variables that reached a significance level 
of p < 0.05 in a univariate analysis were performed to 
identify independent risk factors for mortality. Factors 
of specific interest were also included in the multivari-
ate analyses. Values of p less than 0.05 were considered 
statistically significant.
RESULTS
BASELINE CHARACTERISTICS OF THE STUDY POPULATION
Table 1 lists baseline patient characteristics. Mean age 
was 50.8 ± 12.1 years, 55 patients (42.0%) were men, the 
median PD duration was 81.3 months (range: 7.1 – 202.9 
months), and the median CCI score was 2 (range: 2 – 10). 
All patients were on continuous ambulatory PD.
CLINICAL OUTCOMES
During the follow-up period, 22 patients died 
 (Table 2). The most common cause of death was car-
diovascular disease (45.5%), followed by malignancy 
(22.7%) and infection (22.7%).
COMPARISON BETWEEN SURVIVORS AND NON-SURVIVORS
Table 3 shows the clinical characteristics of survivors 
and non-survivors. The non-survivors were significantly 
older (58.9 ± 9.3 years vs 49.2 ± 12.0 years, p = 0.001) 
and had higher CCI scores (3 vs 2; range: 2 – 10 vs 2 – 
6; p = 0.02), lower percentage LBM (66.8% ± 13.0% vs 
74.8% ± 9.9%, p = 0.001), and higher hsCRP (2.38 mg/
dL vs 1.17 mg/dL; 95% CI: 1.23 to 4.61 mg/dL vs 0.90 
to 1.59 mg/dL; p = 0.03). The L/A ratio (1.06 vs 0.49; 
95% CI: 0.53 to 2.13 vs 0.37 to 0.66; p = 0.03) was sig-
nificantly higher in the non-survivor group, but serum 
leptin levels (15.45 ng/mL vs 8.75 ng/mL; 95% CI: 8.88 
to 26.88 ng/mL vs 6.73 to 11.39 ng/mL; p = 0.06) and 
adiponectin levels (16.7 ± 7.5 μg/mL vs 19.6 ± 7.4 μg/
mL, p = 0.08) were not significantly different between 
the groups.
THE ASSOCIATION OF ADIPOKINES AND L/A RATIO WITH 
METABOLIC FACTORS AND INFLAMMATORY MARKERS
After adjustment for age and sex, correlations be-
tween adipokines and cardiometabolic risk factors were 
estimated using Spearman correlation coefficients 
(Table 4). Plasma leptin was positively correlated with 
BMI (r = 0.42, p < 0.001), LBM (r = 0.28, p = 0.001), 
hsCRP (r = 0.30, p = 0.001), and triglycerides (r = 0.36, 
p < 0.001), and adiponectin was positively correlated 
with HDL cholesterol (r = 0.28, p = 0.002). Negative re-
lations were found between leptin and percentage LBM 
(r = –0.35, p < 0.001) and HDL cholesterol (r = –0.29, p = 
0.002), and adiponectin was negatively correlated with 
BMI (r = –0.38, p < 0.001), hsCRP (r = –0.26, p = 0.005), 
and triglycerides (r = –0.40, p < 0.001). On the other 
TABLE 1 
Baseline Characteristics of the Study Patients
  Variable Value
Mean age (years) 50.8±12.1
Sex (n men/women) 55/76
Mean BMI (kg/m2) 24.6±3.1
Duration of PD (months) 
 Median 81.3
 Range 7.1–202.9
CCI score 
 Median 2
 Range 2–10
Weekly Kt/V urea 1.9±0.3
RRF (mL/min/1.73 m2) 0.3±1.1
Daily nPCR (g/kg) 1.0±0.2
Primary kidney disease [n (%)] 
 Hypertension 49 (37.4)
 Glomerulonephritis 46 (35.1)
 Others 17 (13.0)
 Unknown 19 (14.5)
BMI = body mass index; PD = peritoneal dialysis; CCI = Charlson 
comorbidity index; RRF = residual renal function; nPCR = nor-
malized protein catabolic rate.
TABLE 2 
Deaths in the Study Cohort
 Cause of death [n (%)]
Cardiovascular disease 10 (45.5)
Malignancy 5 (22.7)
Infection 5 (22.7)
Others 2 (9.1)
TOTAL 22
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L/A RATIO AS A PREDICTOR OF PATIENT SURVIVAL
Table 5 shows the results of the univariate Cox pro-
portional hazard analysis for mortality. Higher plasma 
leptin [relative risk (RR): 1.01; 95% CI: 1.01 to 1.03; p = 
0.03], lower plasma adiponectin (RR: 0.94; 95% CI: 0.89 
to 0.99; p = 0.03), and higher L/A ratio (RR: 1.13; 95% 
CI: 1.04 to 1.22; p = 0.003) were significant risk factors 
for mortality. Age (RR: 1.08; 95% CI: 1.04 to 1.13; p = 
0.001), lower serum albumin (RR: 0.31; 95% CI: 0.13 to 
0.84; p = 0.01), higher hsCRP (RR: 1.07; 95% CI: 1.03 to 
1.10; p = 0.001), and higher CCI score (RR: 1.42; 95% CI: 
1.15 to 1.78; p = 0.001) were also found to be associated 
with mortality.
Multivariate Cox proportional hazards analyses of the 
adipokines and L/A ratio revealed that higher leptin (RR: 
1.02; 95% CI: 1.01 to 1.04; p = 0.01), lower adiponectin 
(RR: 0.93; 95% CI: 0.87 to 0.99; p = 0.01), and higher 
L/A ratios (RR: 1.17; 95% CI: 1.07 to 1.27; p = 0.001) 
remained significant predictors of mortality even after 
adjustments for age and serum albumin. However, when 
adjustment was made for age and BMI, the association 
between the L/A ratio and mortality remained significant 
(RR: 1.15; 95% CI: 1.05 to 1.27; p = 0.003), but serum 
leptin and adiponectin were no longer significantly 
hand, the L/A ratio was positively correlated with BMI 
(r = 0.47, p < 0.001), LBM (r = 0.32, p < 0.001), hsCRP (r = 
0.32, p < 0.001), and triglycerides (r = 0.43, p < 0.001). 
Negative associations were observed between the L/A 
ratio and percentage LBM (r = –0.30, p = 0.001) and HDL 
cholesterol (r = –0.31, p = 0.001).
TABLE 3 
Demographic and Laboratory Parameters for Survivors 
and Non-survivors at Study Entry
 Patient group p
  Variable Survivors Non-survivors Value
Patients (n) 109 22 
Mean age (years) 49.2±12.0 58.9±9.3 0.001
Sex (n men/women) 43/66 12/10 0.24
Mean BMI (kg/m2) 24.4±2.6 25.0±2.9 0.38
Duration of PD (months)   
 Median 79.6 85.9 0.48
 Range 7.1–198.4 20.3–202.9 
CCI score   
 Median 2 3 0.02
 Range 2–6 2–10 
Weekly Kt/V urea 2.0±0.3 1.8±0.3 0.09
RRF (mL/min/1.73 m2) 0.3±1.2 0.3±0.9 0.86
Daily nPCR (g/kg) 1.0±0.2 1.0±0.2 0.67
LBM (kg) 43.5±9.5 42.7± 8.8 0.73
Percentage LBM (%) 74.8±9.9 66.8±13.0 0.001
hsCRP (mg/dL)   0.03
 Geometric mean 1.17 2.38 
 95% CI 0.90 to 1.59 1.23 to 4.61 
Fasting glucose (mg/dL) 94.1±17.3 103.5±44.7 0.10
Serum albumin (g/dL) 3.6±0.4 3.4±0.3 0.08
Cholesterol (mg/dL)   
 Total 187.3±41.3 185.2±36.8 0.82
 HDL 46.1±13.8 41.1±8.8 0.11
 LDL 111.2±38.8 113.3±33.2 0.82
Triglycerides (mg/dL)   
 Geometric mean 128.6 137.6 0.60
 95% CI 59.4 to 118.3 113.3 to 173.2 
Leptin (ng/mL)   
 Geometric mean 8.75 15.45 0.06
 95% CI 6.73 to 11.39 8.88 to 26.88 
Adiponectin (μg/mL) 19.6±7.4 16.7±7.5 0.08
Leptin/adiponectin ratio   
 Geometric mean 0.49 1.06 0.03
 95% CI 0.37 to 0.66 0.53 to 2.13 
BMI = body mass index; PD = peritoneal dialysis; CCI = Charlson 
Comorbidity Index; RRF = residual renal function; nPCR = 
normalized protein catabolic rate; LBM = lean body mass; 
hsCRP = high sensitivity C-reactive protein; CI = confidence 
interval; HDL = high-density lipoprotein; LDL = low-density 
lipoprotein.
TABLE 4 
Correlations of Adipokines and Leptin/Adiponectin (L/A)  
Ratio with Metabolic Factors and Inflammatory  
Markers, Adjusted for Age and Sex
  Log Adipo- Log L/A
  leptin nectin ratio
Log leptin — –0.51a 0.95a
Adiponectin –0.51a — –0.74a
Body mass index 0.42a –0.38a 0.47a
Daily nPCR –0.03 0.01 –0.04
LBM 0.28b –0.26b 0.32b
Percentage LBM –0.35b 0.10 –0.30a
Log hsCRP 0.30b –0.26b 0.32a
Serum albumin –0.02 –0.14 0.04
Cholesterol   
 Total 0.83 –0.12 0.67
 HDL –0.29b 0.28b –0.31b
 LDL –0.05 0.13 –0.10
Log triglycerides 0.36a –0.40a 0.43a
nPCR = normalized protein catabolic rate; LBM = lean body 
mass; hsCRP = high sensitivity C-reactive protein; HDL = high-
density lipoprotein; LDL = low-density lipoprotein.
a p < 0.001.
b p < 0.05.
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 associated with mortality. When hsCRP was inserted 
in the model, L/A ratio was no longer associated with 
mortality (Table 6).
DISCUSSION
In the present study, higher L/A ratios were signifi-
cantly associated with increased mortality in nondiabetic 
PD patients. The impact of the L/A ratio on patient sur-
vival remained significant even after adjustments for BMI 
and other confounding variables, including age, serum 
albumin, and BMI.
Although high plasma leptin and low plasma adi-
ponectin have been demonstrated to be risk factors for 
cardiovascular diseases in the nonuremic population 
(5,7), similar evidence is less clear in chronic kidney 
disease patients. Low plasma adiponectin was found to be 
independently associated with cardiovascular outcomes 
in ESRD patients (19,20), but high (rather than low) 
plasma adiponectin was linked with increased mortality 
in early chronic kidney disease patients (21). In addition, 
a relevant relationship between plasma leptin and vascu-
lar diseases was not definitive in a cohort of mixed HD and 
PD patients (13). Moreover, a recent report showed that 
low plasma leptin predicted mortality in ESRD patients 
on HD (12), which did not accord with results of previous 
studies in the general population or with the results of 
the present study.
We surmise that the opposing results for the associa-
tion between plasma leptin and death are partly a result 
of differences in the study populations. Unlike the case 
in HD, PD is characterized by a gain of fat mass because 
of the excessive glucose load from the dialysate (22). 
This altered glucose and fat metabolism leads to an 
extraordinarily high plasma leptin level in PD patients 
(4). Compared with the results of the aforementioned 
study (12), BMI (mean: 22.9 kg/m2 vs 24.5 kg/m2) and 
plasma leptin (median: 2.6 ng/mL vs 10.1 ng/mL) were 
higher in the present study. As mentioned by Scholze et 
al. (12), low plasma leptin in HD patients might represent 
a state of malnutrition, but the distinctively high plasma 
leptin in PD patients might be a consequence of altered 
glucose and fat metabolism.
Leptin and adiponectin have pleiotropic functions 
that might influence outcomes. However, the impacts 
of these two adipokines on clinical outcome seem to be 
commonly attributed to their effect on inflammation. 
In addition to its accepted effect in limiting food intake 
(23), leptin affects the production of proinflammatory 
TABLE 5 
Hazard Ratios (HRs) and 95% Confidence Intervals (CIs) 
for Mortality by Univariate Cox Proportional  
Hazards Analysis
   p
 Variable HR 95% CI Value
Age (years) 1.08 1.04 to 1.13 0.001
Sex (male) 0.58 0.25 to 1.34 0.20
CCI score 1.42 1.15 to 1.78 0.001
Serum albumin (g/dL) 0.31 0.13 to 0.84 0.01
hsCRP (mg/dL) 1.07 1.03 to 1.10 0.001
BMI (kg/m2) 1.08 0.91 to 1.28 0.36
Leptin (ng/mL) 1.01 1.01 to 1.03 0.03
Adiponectin (μg/mL) 0.94 0.89 to 0.99 0.03
L/A ratio 1.13 1.04 to 1.22 0.003
CCI = Charlson comorbidity index; hsCRP = high sensitivity 
C-reactive protein; BMI = body mass index; L/A = leptin/
adiponectin.
TABLE 6 
Hazard Ratios (HRs) and 95% Confidence Intervals (CIs) for Mortality According to Serum Level of Adipokines and 
Leptin/Adiponectin (L/A) Ratio, by Multivariate Cox Proportional Hazards Analysis
 Leptin Adiponectin L/A ratio
   p   p   p
 HR 95% CI Value HR 95% CI Value HR 95% CI Value
Model 1a 1.02 1.01 to 1.03 0.03 0.94 0.89 to 0.99 0.03 1.17 1.07 to 1.27 0.001
Model 2b 1.02 1.01 to 1.04 0.01 0.93 0.87 to 0.99 0.01 1.17 1.07 to 1.27 0.001
Model 3c 1.02 0.99 to 1.03 0.06 0.95 0.89 to 1.02 0.14 1.15 1.05 to 1.27 0.003
Model 4d 1.01 0.99 to 1.03 0.17 0.95 0.90 to 1.01 0.09 1.10 0.97 to 1.25 0.15
a Adjusted for age.
b Adjusted for age and serum albumin.
c Adjusted for age and body mass index.
d Adjusted for age and high sensitivity C-reactive protein.
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cytokines (24). On the other hand, beyond its primary 
insulin-sensitizing effect (25), adiponectin has a direct 
anti-inflammatory effect, partially because of reduced 
production of tumor necrosis factor α (24). The actions of 
these adipokines on inflammation are also supported by 
the findings of the present study, in which plasma leptin 
and adiponectin and the L/A ratio are all significantly 
correlated with hsCRP. In addition, even though the L/A 
ratio predicted mortality, the fact that its significance 
disappeared after adjustment for hsCRP suggests that 
the association between L/A ratio and mortality may be 
mediated through inflammation.
Leptin and adiponectin are closely related to adipo-
cyte mass. Leptin increases and adiponectin decreases 
with the increase of fat mass (5,7,26). Recently, it has 
also been postulated that adipose tissue contributes 
to the chronic inflammatory state commonly observed 
in PD patients (27,28). To evaluate whether changes in 
adipokine levels play a direct role in patient outcomes 
or merely act as an epiphenomenon of adiposity in-
fluencing systemic inflammation, adjustments were 
made for BMI in the Cox proportional hazards analysis. 
Although the significances of leptin and adiponectin 
disappeared after adjustments including BMI, the L/A 
ratio remained a considerable risk. Those f indings 
suggest that the balance of these adipokines may influ-
ence clinical outcomes in PD patients independently 
of the well-known cardiovascular problems caused by 
adiposity itself.
Interestingly, in the present study, we observed a 
positive correlation between plasma leptin and LBM, 
and an inverse association between plasma leptin and 
percentage LBM. Because LBM was estimated by crea-
tinine kinetics, we presumed that LBM represented not 
only the actual fat-free component of the body, but also 
nutrition status. Peritoneal dialysis patients with higher 
LBM were therefore supposed to be in better state of 
nutrition and thus to have both higher fat and muscle 
mass. By contrast, the percentage LBM was considered 
better than LBM at representing the fat-free portion. 
That assumption was partially supported by the results 
of the present study, in that LBM was strongly positively 
correlated with BMI (r = 0.23, p = 0.005), but we observed 
a trend of negative correlation between percentage LBM 
and BMI (r = –0.14, p = 0.09). Consequently, given that 
previous studies have demonstrated that leptin is closely 
related to fat mass, we speculate that the positive asso-
ciation between leptin and LBM in the present study is 
rather a result of the relationship with fat content, and 
that the inverse correlation of leptin with percentage 
LBM reflects the negative relationship between leptin 
and fat-free mass. To verify that hypothesis, further 
studies that include a precise measurement of fat mass 
will be needed.
On the other hand, a recent study by Stenvinkel et al. 
(29) found a negative correlation between plasma lep-
tin and the change in LBM over time. Even though they 
found that patients with higher baseline levels of leptin 
eventually lost LBM after 1 year, no significant associa-
tion was observed between baseline leptin and baseline 
LBM, which differs from the results in the present study. 
The fact that the former study population consisted of 
both diabetic and nondiabetic patients and that our 
study included only nondiabetic patients and also used 
a different method to assess LBM may in part contribute 
to the discrepancy.
Previous studies have demonstrated a wide variation 
in the L/A ratio depending on the study population. No 
solid ranges of normal L/A values have yet been reported 
in the Asian population. A recent study showed that the 
mean L/A ratio was 0.85 for non-obese men in the gen-
eral population; in obese patients, the mean L/A ratio 
was 2.81 (10). In ESRD patients, higher levels of plasma 
leptin with comparable levels of plasma adiponectin were 
observed in PD patients compared with HD patients (13), 
resulting in higher L/A ratios in PD patients, which is in 
part attributed to the weight gain caused by the excessive 
glucose load from PD fluid (22) and to the impact of PD 
solutions on adipokine levels [they increase leptin while 
adiponectin in adipocytes decreases (4,30)].
The present study has several limitations. First, even 
though the cohort was relatively large for a single-center 
study, the number of events was rather small, limiting the 
power of the statistical analysis to identify independent 
risk factors for mortality. Therefore, to maintain the 
statistical power, only two factors at a time could be 
evaluated in the multivariate analysis. Second, single 
measurements of adipokines at baseline were used for 
the analysis. Still, measurements of plasma leptin and 
adiponectin have been reported to show a high degree of 
reproducibility even when taken 1 – 4 years apart, sug-
gesting that a single measurement may be sufficient for 
risk assessment (31). Lastly, the measurement of body 
composition, especially muscle and fat, was incomplete 
and not precise. A more accurate method to assess body 
composition should be used in future studies to better 
understand the relationship between adipokines and 
body composition.
CONCLUSIONS
Higher L/A ratios were associated with increased 
mortality even after adjusting for various confound-
ing variables such as age, serum albumin, and BMI in 
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nondiabetic PD patients, suggesting that the balance 
between those two adipokines may play a significant role 
in clinical outcomes in this population with metabolic 
disturbance. Further studies are required to confirm 
whether therapeutic strategies that lower the L/A ratio, 
such as the use of glucose-sparing PD regimens and 
treatment with peroxisome proliferator-activated recep-
tor agonists, might improve survival in nondiabetic PD 
patients.
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